Research and Markets: World Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Pipeline Review, H2 2015 - 30 Companies & 19 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/w6slwq/ankylosing) has announced the addition of the "Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Amgen Inc.
  • Avesthagen Limited
  • BIOCAD
  • Biocon Limited
  • Bionovis SA
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Genor BioPharma Co., Ltd.
  • Hetero Drugs Limited
  • Inbiopro Solutions Pvt. Ltd.
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Lupin Limited
  • Mabion SA
  • Mabtech Limited
  • Momenta Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Oncobiologics, Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • Sandoz International GmbH
  • Shanghai Pharmaceutical Co., Ltd.
  • Therapeutic Proteins International, LLC
  • Vitae Pharmaceuticals, Inc.
  • Xbrane Bioscience AB

Drug Profiles

  • adalimumab biosimilar
  • apremilast
  • BI-655066
  • certolizumab pegol biosimilar
  • COVA-322
  • DNX-114
  • DNX-514
  • etanercept biosimilar
  • golimumab
  • golimumab biosimilar
  • IBI-303
  • IBPM-004AM
  • IBPM-005IX
  • infliximab biosimilar
  • INV-17
  • secukinumab
  • thalidomide
  • tofacitinib
  • VTP-43742

For more information visit http://www.researchandmarkets.com/research/w6slwq/ankylosing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals